| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 40.5 | 32.8 | 0.0 |
| Other income | 0.9 | 0.3 | 0.0 |
| Total income | 41.4 | 33.1 | 0.0 |
| Profit before exceptional items & tax | 2.4 | 2.0 | 0.0 |
| Profit before tax | 2.4 | 2.0 | 0.0 |
| Net profit | 2.0 | 0.9 | 0.0 |
| Operating margin | 5.8% | 6.0% | 0.0% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, quarter on quarter | +122.20% |
|---|
NSE results filing, NSE: AMBEY. Figures extracted from the filing.
More from Ambey Laboratories Limited
All →Ambey Laboratories Financial Results
Ambey Laboratories Limited approved its audited FY26 financial results, reporting consolidated revenue of ₹141.54 Crore. The board also reviewed fund utilization and related party disclosures.
Ambey Laboratories Other Announcement
Dhansa Labs Limited submitted its annual SDD Compliance Certificate for the financial year 2026. This confirms regulatory adherence to SEBI insider trading monitoring requirements.
Ambey Laboratories Other Announcement
Ambey Laboratories Limited will change its name to Dhansa Labs Limited and its NSE symbol to DHANSA. The change is effective from June 01, 2026.
Ambey Laboratories Capital Structure Change
Dhansa Labs Limited allotted 3,63,043 equity shares following warrant conversions, raising ₹1.67 Crore. This exercise increases the company's paid-up capital and strengthens its equity base.
- Value
- ₹1.67 Cr
Ambey Laboratories Board Meeting Date
Ambey Laboratories scheduled a board meeting on May 29, 2026, to approve audited annual financial results. The company's trading window remains closed until May 31, 2026.
Ambey Laboratories Annual General Meeting
Dhansa Labs Limited submitted a missing Chartered Accountant's Certificate regarding its postal ballot process. The certificate confirms compliance with rebranding regulations for its name change.